Results 151 to 160 of about 807 (164)

Cost-effectiveness of Azvudine for High-risk Outpatients with Mild-to-moderate Coronavirus Disease 2019 in China

Clinical Therapeutics
This study aimed to evaluate the cost-effectiveness of Azvudine for the treatment of mild-to-moderate coronavirus disease 2019 in high-risk outpatients using real-world data and relevant references.In the decision-tree model, 2 cohorts were organized in a single center to compare the cost-effectiveness between the Azvudine plus symptomatic treatment ...
Hui, Yang, Zhaojian, Wang, Chunping, Wang, Ying, Zhang, Sheng, Han, Zhuoling, An   +5 more
openaire   +2 more sources

Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study

EClinicalMedicine, 2023
Minxue Shen, Furong Zeng, Guangtong Deng   +2 more
exaly  

Real‐world effectiveness of Azvudine versus nirmatrelvir–ritonavir in hospitalized patients with COVID‐19: A retrospective cohort study

Journal of Medical Virology, 2023
Guangtong Deng, Furong Zeng, Pinhua Pan   +2 more
exaly  

Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: Results of a real‐world study

Journal of Medical Virology, 2023
Yushu Wang, Xuefeng Liu, Zhuoling An
exaly  

Azvudine Reduce the In-Hospital Mortality of Patients with COVID-19 Pneumonia

2023
Kaican Zong, Hui Zhou, Wen Li, E Jiang, Yi Liu, Shiying Li   +5 more
openaire   +1 more source

Real‐world effectiveness of Azvudine versus nirmatrelvir‐ritonavir in hospitalized patients with COVID‐19

Journal of Medical Virology, 2023
Guangting Zeng, Linlin Wang, Jianqiang Li, Zanling Zhang   +3 more
openaire   +2 more sources

Azvudine

Reactions Weekly
openaire   +2 more sources

Azvudine and nirmatrelvir–ritonavir in hospitalized patients with moderate‐to‐severe COVID‐19: Emulation of a randomized target trial

Journal of Medical Virology, 2023
Yiling Zhou, Xing Zhao, Sheyu Li
exaly  

A Randomized, Open‐Label, Controlled Clinical Trial of Azvudine Tablets in the Treatment of Mild and Common COVID‐19, a Pilot Study

Advanced Science, 2020
Zhigang Ren, Zujiang Yu, Guangying Cui   +2 more
exaly  

Azvudine/ibrutinib

Reactions Weekly
openaire   +1 more source